AMCP holds various meetings, forums, symposia, summits and other gatherings of experts to discuss topics of importance to managed care pharmacy. This section contains proceedings and findings and other documents that result from these events.
AMCP Partnership Forums bring together payers, pharmacies, integrated delivery system leaders, HEOR analysts, academics, providers, pharmaceutical manufacturers and various other health care stakeholders to discuss key issues facing managed care pharmacy and collaboratively help shape the changing health care landscape. The events are invitation only and are supported by our partners. The findings from the forums are shared with members via webinars and proceedings published in the Journal of Managed Care & Specialty Pharmacy.
- For past Partnership Forums, please visit Meeting Proceedings & Findings in our Resource Center.
- Learn more about sponsoring a Partnership Forum.
Helping Patients Anticipate and Manage Drug Costs
As local and national legislators and regulators consider ways to curb the rising cost of pharmaceuticals, what remains unknown are the intended and unintended consequences to patients of proposed actions, including potential changes to rebates for federal programs, requirements for public disclosure and transparency of drug prices, and the role of PBMs and health plans. Participants will consider the possible solutions for addressing rising costs and discuss challenges, practical steps for implementing point of sale rebates and other proposed solutions, and discuss how patient assistance programs and copay policies fit into the affordability equation. This forum will develop recommendations and possible solutions to improve price transparency, address the rising costs of medications, and help patient understand and manage drug cost.
March 12-13, 2020| The Alexandrian Old Town , Alexandria, VA
Preparing for and Managing Rare Diseases
The advent of million-dollar therapies for rare diseases brings concerns for how managed care organizations (MCOs) will evaluate evidence, provide access and manage outcomes for these therapies in an environment of limited health care resources. This forum will discuss the role of MCOs, life science companies, prescribers, patients, employers, and the government in supporting access to breakthrough therapies, identifying and managing these small but important populations of patients, and collecting real-world data on patient outcomes. This forum will identify key actions that can support access to and the appropriate management of treatments for rare diseases within the U.S. health care system.
September 8-10, 2020| Virtual Meeting
Biosimilars: Policy, Practice, and Post Marketing Surveillance to Support Treatment and Coverage
The market for biologic drugs in the United States is large and has the potential to play an increasingly important role in the country’s health care system — both in the treatment of disease and in the affordability of drugs. Biosimilar approval and marketing of products in the United States is at a slower pace than desired by many stakeholders. Given widespread interest in curbing drug spending, policymakers and others are interested in the viability of biologic market competition to reduce prices. There are also barriers to biosimilar adoption that are independent of payment policy or regulatory approval but are nonetheless important for the evolution of this market. For example, health care providers need greater awareness and understanding of biosimilars to increase confidence in their safety and effectiveness. In addition, post-marketing evidence generation for novel biologics, their corresponding biosimilars, and other related products is important for treatment and coverage decisions. This forum will identify key actions that can support the further development and use of biologics in the U.S. health care system.
December 15-16, 2020 | The Alexandrian Old Town , Alexandria, VA
WORKGROUP - Addressing Barriers to Value-based Payment Models in Integrated Delivery Networks
Collaborate with a group of key stakeholders to address how existing laws are impacting integrated delivery networks (IDNs) and pharmaceutical partnerships. Legal and regulatory requirements (e.g., the Anti-Kickback Statute and Medicaid best price rule) can limit the use of certain strategies that could potentially improve care coordination and patient outcomes. Successful implementation of value-based agreements in IDNs requires a range of complex capabilities. The workgroup will provide examples of real-world challenges and possible solutions that will inform and support efforts for legislative change.